Non-contrast short MRI surveillance for HCC screening : the study protocol of the SMS-HCC prospective multicenter study
© 2024. The Author(s)..
Hepatocellular carcinoma (HCC) comprises 75 to 85% of all primary liver cancers. Current guidelines recommend a biannual HCC surveillance using ultrasound (US) for high-risk patients. However, due to its low sensitivity for detection of early-stage HCC lesions, there is an urgency for more sensitive surveillance tools. Here, we describe the potential of a short MRI surveillance (SMS) protocol for HCC, including axial T1-weighted in-out phase, fat-saturated T2-weighted, and diffusion-weighted sequences. In this prospective, multicenter, patient cohort study, patients will be recruited from existing HCC surveillance cohorts of six medical centers in The Netherlands. Surveillance patients who undergo biannual US, will be invited for SMS on the same day for 3 years. In case of a suspicious finding on either US or SMS, patients will be invited for a full MRI liver protocol including gadolinium-based contrast agent intravenous injection within 2 weeks. To our knowledge, this will be the first study to perform a head-to-head comparison with a paired US-MRI design. We hypothesize that the sensitivity of SMS for detection of early-stage HCC will be higher than that of US leading to improved survival of surveillance patients through timely HCC diagnosis. Furthermore, we hypothesize that the SMS-HCC protocol will prove cost-effective.Relevance statement The US sensitivity for detecting early-stage HCC has been reported to be less than 50%. We expect that the proposed SMS will detect at least twice as many early-stage HCC lesions and therefore prove to be cost-effective. Key points • The low sensitivity of US necessitates better imaging tools for HCC screening.• This is the first study with a paired US-MRI design.• This design will allow a head-to-head comparison in both diagnostics and patient-acceptance.• We expect that SMS can contribute to a higher survival rate.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
European radiology experimental - 8(2024), 1 vom: 12. März, Seite 29 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
van de Braak, Céline [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Contrast Media |
|---|
| Anmerkungen: |
Date Completed 13.03.2024 Date Revised 15.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s41747-024-00432-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369577167 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369577167 | ||
| 003 | DE-627 | ||
| 005 | 20240315233602.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240312s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s41747-024-00432-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1330.xml |
| 035 | |a (DE-627)NLM369577167 | ||
| 035 | |a (NLM)38467990 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a van de Braak, Céline |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Non-contrast short MRI surveillance for HCC screening |b the study protocol of the SMS-HCC prospective multicenter study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.03.2024 | ||
| 500 | |a Date Revised 15.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Hepatocellular carcinoma (HCC) comprises 75 to 85% of all primary liver cancers. Current guidelines recommend a biannual HCC surveillance using ultrasound (US) for high-risk patients. However, due to its low sensitivity for detection of early-stage HCC lesions, there is an urgency for more sensitive surveillance tools. Here, we describe the potential of a short MRI surveillance (SMS) protocol for HCC, including axial T1-weighted in-out phase, fat-saturated T2-weighted, and diffusion-weighted sequences. In this prospective, multicenter, patient cohort study, patients will be recruited from existing HCC surveillance cohorts of six medical centers in The Netherlands. Surveillance patients who undergo biannual US, will be invited for SMS on the same day for 3 years. In case of a suspicious finding on either US or SMS, patients will be invited for a full MRI liver protocol including gadolinium-based contrast agent intravenous injection within 2 weeks. To our knowledge, this will be the first study to perform a head-to-head comparison with a paired US-MRI design. We hypothesize that the sensitivity of SMS for detection of early-stage HCC will be higher than that of US leading to improved survival of surveillance patients through timely HCC diagnosis. Furthermore, we hypothesize that the SMS-HCC protocol will prove cost-effective.Relevance statement The US sensitivity for detecting early-stage HCC has been reported to be less than 50%. We expect that the proposed SMS will detect at least twice as many early-stage HCC lesions and therefore prove to be cost-effective. Key points • The low sensitivity of US necessitates better imaging tools for HCC screening.• This is the first study with a paired US-MRI design.• This design will allow a head-to-head comparison in both diagnostics and patient-acceptance.• We expect that SMS can contribute to a higher survival rate | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Hepatitis | |
| 650 | 4 | |a Hepatocellular carcinoma | |
| 650 | 4 | |a Liver cirrhosis | |
| 650 | 4 | |a Magnetic resonance imaging | |
| 650 | 4 | |a Ultrasonography | |
| 650 | 7 | |a Contrast Media |2 NLM | |
| 700 | 1 | |a Willemssen, François E J A |e verfasserin |4 aut | |
| 700 | 1 | |a de Man, Rob A |e verfasserin |4 aut | |
| 700 | 1 | |a van der Lugt, Aad |e verfasserin |4 aut | |
| 700 | 1 | |a Uyl-de Groot, Carin A |e verfasserin |4 aut | |
| 700 | 1 | |a Bos, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Dwarkasing, Roy S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European radiology experimental |d 2017 |g 8(2024), 1 vom: 12. März, Seite 29 |w (DE-627)NLM283556358 |x 2509-9280 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2024 |g number:1 |g day:12 |g month:03 |g pages:29 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s41747-024-00432-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2024 |e 1 |b 12 |c 03 |h 29 | ||